Indications
Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
Composition
- Active substance
- temsirolimus
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Torisel
- Active substance
- temsirolimus
- ATC code
- L01XE09
- Therapeutic area
- Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
- Marketing authorisation holder